Predominance of AT1 blockade over mas-mediated angiotensin-(1-7) mechanisms in the regulation of blood pressure and renin-angiotensin system in mRen2.Lewis rats

American Journal of Hypertension

Volumn 26, Issue 5, 2013, Pages 583-590

  Varagic, Jasmina ^a,b   Ahmad, Sarfaraz ^b   Voncannon, Jessica L ^a,b   Moniwa, Norihito ^b   Bridget Brosnihan, K ^a,b   Wysocki, Jan ^c   Batlle, Daniel ^c   Ferrario, Carlos M ^a,b  

^a WAKE FOREST SCHOOL OF MEDICINE   (United States)

^b WAKE FOREST UNIVERSITY   (United States)

^c NORTHWESTERN UNIVERSITY   (United States)

Author keywords

angiotensin II; angiotensin (1 7); AT1 receptor; blood pressure; heart; hypertension; kidney; mas receptor; olmesartan

Indexed keywords

ALDOSTERONE; ANGIOTENSIN CONVERTING ENZYME 2; ANGIOTENSIN I; ANGIOTENSIN II; ANGIOTENSIN[1-7]; ANGIOTENSIN[1-7][7 DEXTRO ALANINE]; BICARBONATE; OLMESARTAN; PEPTIDE;

ALDOSTERONE BLOOD LEVEL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD PRESSURE REGULATION; CONTROLLED STUDY; ENZYME ACTIVITY; HYPERTENSION; KIDNEY; MALE; NONHUMAN; OSMOTIC MINIPUMP; PLASMA RENIN ACTIVITY; PRIORITY JOURNAL; RAT; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; TELEMETRY;

ALDOSTERONE; ANGIOTENSIN I; ANGIOTENSIN II; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANIMALS; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; DISEASE MODELS, ANIMAL; HYPERTENSION; IMIDAZOLES; MALE; PEPTIDE FRAGMENTS; PROTO-ONCOGENE PROTEINS; RATS; RATS, INBRED LEW; RATS, TRANSGENIC; RECEPTOR, ANGIOTENSIN, TYPE 1; RECEPTORS, G-PROTEIN-COUPLED; RENIN; RENIN-ANGIOTENSIN SYSTEM; TETRAZOLES;

EID: 84876588807     PISSN: 08957061     EISSN: 19417225     Source Type: Journal    
DOI: 10.1093/ajh/hps090     Document Type: Article

References (47)

1. Schindler C, Ferrario CM. Olmesartan for the treatment of arterial hypertension. Future Cardiol 2008;4:357-372. (Pubitemid 351984033)
2. Agata J, Ura N, Yoshida H, Shinshi Y, Sasaki H, Hyakkoku M, Taniguchi S, Shimamoto K. Olmesartan is an angiotensin II receptor blocker with an inhibitory effect on angiotensin-converting enzyme. Hypertens Res 2006;29:865-874. (Pubitemid 46062117)
3. Ferrario CM, Jessup J, Gallagher PE, Averill DB, Brosnihan KB, Tallant EA, Smith RD, Chappell MC. Effects of renin-angiotensin system blockade on renal angiotensin-(1-7) forming enzymes and receptors. Kidney Int 2005;68:2189-2196. (Pubitemid 43117793)
4. Ferrario CM, Jessup J, Chappell MC, Averill DB, Brosnihan KB, Tallant EA, Diz DI, Gallagher PE. Effect of angiotensin-converting enzyme inhibition and angiotensin II receptor blockers on cardiac angiotensinconverting enzyme 2. Circulation 2005;111:2605-2610. (Pubitemid 40740859)
5. Deddish PA, Marcic B, Jackman HL, Wang HZ, Skidgel RA, Erdos EG. N-domain-specific substrate and C-domain inhibitors of angiotensinconverting enzyme: angiotensin-(1-7) and keto-ACE. Hypertension 1998;31:912-917. (Pubitemid 28185567)
6. Roks AJ, van Geel PP, Pinto YM, Buikema H, Henning RH, de ZD, van Gilst WH. Angiotensin-(1-7) is a modulator of the human renin-angiotensin system. Hypertension 1999;34:296-301. (Pubitemid 29409231)
7. Ichikawa S, Takayama Y. Long-term effects of olmesartan, an Ang II receptor antagonist, on blood pressure and the renin-angiotensinaldosterone system in hypertensive patients. Hypertens Res 2001;24: 641-646. (Pubitemid 33133777)
8. Tsutamoto T, Nishiyama K, Yamaji M, Kawahara C, Fujii M, Yamamoto T, Horie M. Comparison of the long-term effects of candesartan and olmesartan on plasma angiotensin II and left ventricular mass index in patients with hypertension. Hypertens Res 2010;33:118-122.
9. Igase M, Strawn WB, Gallagher PE, Geary RL, Ferrario CM. Angiotensin II AT1 receptors regulate ACE2 and angiotensin-(1-7) expression in the aorta of spontaneously hypertensive rats. Am J Physiol Heart Circ Physiol 2005;289:H1013-H1019. (Pubitemid 41208941)
10. Wysocki J, Ye M, Rodriguez E, Gonzalez-Pacheco FR, Barrios C, Evora K, Schuster M, Loibner H, Brosnihan KB, Ferrario CM, Penninger JM, Batlle D. Targeting the degradation of angiotensin II with recombinant angiotensin-converting enzyme 2: prevention of angiotensin II-dependent hypertension. Hypertension 2010;55:90-98.
11. Gallagher PE, Ferrario CM, Tallant EA. Regulation of ACE2 in cardiac myocytes and fibroblasts. Am J Physiol Heart Circ Physiol 2008;295:H2373-H2379.
12. Benter IF, Yousif MH, Al-Saleh FM, Raghupathy R, Chappell MC, Diz DI. Angiotensin-(1-7) blockade attenuates captopril-or hydralazineinduced cardiovascular protection in spontaneously hypertensive rats treated with NG-nitro-L-arginine methyl ester. J Cardiovasc Pharmacol 2011;57:559-567.
13. Raffai G, Durand MJ, Lombard JH. Acute and chronic angiotensin-( 1-7) restores vasodilation and reduces oxidative stress in mesenteric arteries of salt-fed rats. Am J Physiol Heart Circ Physiol 2011; 301:H1341-H1352.
14. Tallant EA, Ferrario CM, Gallagher PE. Angiotensin-(1-7) inhibits growth of cardiac myocytes through activation of the mas receptor. Am J Physiol Heart Circ Physiol 2005;289:H1560-H1566. (Pubitemid 41368998)
15. Chappell MC, Gallagher PE, Averill DB, Ferrario CM, Brosnihan KB. Estrogen or the AT1 antagonist olmesartan reverses the development of profound hypertension in the congenic mRen2. Lewis rat. Hypertension 2003;42:781-786. (Pubitemid 37237325)
16. Jessup JA, Gallagher PE, Averill DB, Brosnihan KB, Tallant EA, Chappell MC, Ferrario CM. Effect of angiotensin II blockade on a new congenic model of hypertension derived from transgenic Ren-2 rats. Am J Physiol Heart Circ Physiol 2006;291:H2166-H2172.
17. Trask AJ, Groban L, Westwood BM, Varagic J, Ganten D, Gallagher PE, Chappell MC, Ferrario CM. Inhibition of angiotensin-converting enzyme 2 exacerbates cardiac hypertrophy and fibrosis in Ren-2 hypertensive rats. Am J Hypertens 2010;23:687-693.
18. Allred AJ, Diz DI, Ferrario CM, Chappell MC. Pathways for angiotensin-( 1-7) metabolism in pulmonary and renal tissues. Am J Physiol Renal Physiol 2000;279:F841-F850.
19. Velez JC, Ierardi JL, Bland AM, Morinelli TA, Arthur JM, Raymond JR, Janech MG. Enzymatic processing of angiotensin peptides by human glomerular endothelial cells. Am J Physiol Renal Physiol 2012; 302:F1583-F1594.
20. Walters PE, Gaspari TA, Widdop RE. Angiotensin-(1-7) acts as a vasodepressor agent via angiotensin II type 2 receptors in conscious rats. Hypertension 2005;45:960-966. (Pubitemid 40628944)
21. Widdop RE, Sampey DB, Jarrott B. Cardiovascular effects of angiotensin-( 1-7) in conscious spontaneously hypertensive rats. Hypertension 1999;34:964-968. (Pubitemid 29501331)
22. Benter IF, Diz DI, Ferrario CM. Cardiovascular actions of angiotensin-( 1-7). Peptides 1993;14:679-684.
23. Benter IF, Ferrario CM, Morris M, Diz DI. Antihypertensive actions of angiotensin-(1-7) in spontaneously hypertensive rats. Am J Physiol 1995;269:H313-H319.
24. Benter IF, Yousif MH, Anim JT, Cojocel C, Diz DI. Angiotensin-(1-7) prevents development of severe hypertension and end-organ damage in spontaneously hypertensive rats treated with L-NAME. Am J Physiol Heart Circ Physiol 2006;290:H684-H691.
25. Burgelova M, Vanourkova Z, Thumova M, Dvorak P, Opocensky M, Kramer HJ, Zelizko M, Maly J, Bader M, Cervenka L. Impairment of the angiotensin-converting enzyme 2-angiotensin-(1-7)-Mas axis contributes to the acceleration of two-kidney, one-clip Goldblatt hypertension. J Hypertens 2009;27:1988-2000.
26. Al-Maghrebi M, Benter IF, Diz DI. Endogenous angiotensin-(1-7) reduces cardiac ischemia-induced dysfunction in diabetic hypertensive rats. Pharmacol Res 2009;59:263-268.
27. Collister JP, Nahey DB. Simultaneous administration of Ang(1-7) or A-779 does not affect the chronic hypertensive effects of angiotensin II in normal rats. J Renin Angiotensin Aldosterone Syst 2010;11:99-102.
28. Iyer SN, Yamada K, Diz DI, Ferrario CM, Chappell MC. Evidence that prostaglandins mediate the antihypertensive actions of angiotensin-( 1-7) during chronic blockade of the renin-angiotensin system. J Cardiovasc Pharmacol 2000;36:109-117. (Pubitemid 30419130)
29. Tallant EA, Lu X, Weiss RB, Chappell MC, Ferrario CM. Bovine aortic endothelial cells contain an angiotensin-(1-7) receptor. Hypertension 1997;29:388-393. (Pubitemid 27074073)
30. Ferrario C. Effect of angiotensin receptor blockade on endothelial function: focus on olmesartan medoxomil. Vasc Health Risk Manag 2009;5:301-314.
31. Ferrario CM, Smith RD: Role of olmesartan in combination therapy in blood pressure control and vascular function. Vasc Health Risk Manag 2010;6:701-709.
32. Cohn JN, Anand IS, Latini R, Masson S, Chiang YT, Glazer R. Sustained reduction of aldosterone in response to the angiotensin receptor blocker valsartan in patients with chronic heart failure: results from the Valsartan Heart Failure Trial. Circulation 2003;108:1306-1309. (Pubitemid 37179882)
33. Yoneda T, Takeda Y, Usukura M, Oda N, Takata H, Yamamoto Y, Karashima S, Yamagishi M. Aldosterone breakthrough during angiotensin II receptor blockade in hypertensive patients with diabetes mellitus. Am J Hypertens 2007;20:1329-1333. (Pubitemid 350151696)
34. Siragy HM, Inagami T, Carey RM. NO and cGMP mediate angiotensin AT2 receptor-induced renal renin inhibition in young rats. Am J Physiol Regul Integr Comp Physiol 2007;293:R1461-R1467. (Pubitemid 47535763)
35. Varagic J, Ahmad S, Brosnihan KB, Habibi J, Tilmon RD, Sowers JR, Ferrario CM. Salt-induced renal injury in spontaneously hypertensive rats: effects of nebivolol. Am J Nephrol 2010;32:557-566.
36. Kobori H, Prieto-Carrasquero MC, Ozawa Y, Navar LG. AT1 receptor mediated augmentation of intrarenal angiotensinogen in angiotensin II-dependent hypertension. Hypertension 2004;43:1126-1132. (Pubitemid 38579925)
37. Nishiyama A, Seth DM, Navar LG. Angiotensin II type 1 receptormediated augmentation of renal interstitial fluid angiotensin II in angiotensin II-induced hypertension. J Hypertens 2003;21:1897-1903. (Pubitemid 37290108)
38. Takahashi Y, Haga S, Ishizaka Y, Mimori A. Autoantibodies to angiotensin-converting enzyme 2 in patients with connective tissue diseases. Arthritis Res Ther 2010;12:R85.
39. Burchill L, Velkoska E, Dean RG, Lew RA, Smith AI, Levidiotis V, Burrell LM. Acute kidney injury in the rat causes cardiac remodelling and increases angiotensin-converting enzyme 2 expression. Exp Physiol 2008;93:622-630. (Pubitemid 351595052)
40. Arumugam S, Thandavarayan RA, Palaniyandi SS, Giridharan VV, Arozal W, Sari FR, Soetikno V, Harima M, Suzuki K, Kodama M, Watanabe K. Candesartan cilexetil protects from cardiac myosin induced cardiotoxicity via reduction of endoplasmic reticulum stress and apoptosis in rats: involvement of ACE2-Ang (1-7)-mas axis. Toxicology 2012;291:139-145.
41. Lew RA, Warner FJ, Hanchapola I, Yarski MA, Manohar J, Burrell LM, Smith AI. Angiotensin-converting enzyme 2 catalytic activity in human plasma is masked by an endogenous inhibitor. Exp Physiol 2008;93:685-693. (Pubitemid 351595050)
42. Casarini DE, Boim MA, Stella RC, Schor N. Endopeptidases (kininases) are able to hydrolyze kinins in tubular fluid along the rat nephron. Am J Physiol 1999;277:F66-F74. (Pubitemid 29352676)
43. Santos RA, Brosnihan KB, Jacobsen DW, DiCorleto PE, Ferrario CM. Production of angiotensin-(1-7) by human vascular endothelium. Hypertension 1992;19:II56-II61.
44. Welches WR, Brosnihan KB, Ferrario CM. A comparison of the properties and enzymatic activities of three angiotensin processing enzymes: angiotensin converting enzyme, prolyl endopeptidase and neutral endopeptidase 24.11. Life Sci 1993;52:1461-1480.
45. Gonzalez-Villalobos R, Klassen RB, Allen PL, Johanson K, Baker CB, Kobori H, Navar LG, Hammond TG. Megalin binds and internalizes angiotensin-(1-7). Am J Physiol Renal Physiol 2006;290: F1270-F1275. (Pubitemid 43724928)
46. Hosojima M, Sato H, Yamamoto K, Kaseda R, Soma T, Kobayashi A, Suzuki A, Kabasawa H, Takeyama A, Ikuyama K, Iino N, Nishiyama A, Thekkumkara TJ, Takeda T, Suzuki Y, Gejyo F, Saito A. Regulation of megalin expression in cultured proximal tubule cells by angiotensin II type 1A receptor-and insulin-mediated signaling cross talk. Endocrinology 2009;150:871-878.
47. Whaley-Connell A, Habibi J, Nistala R, Hayden MR, Pulakat L, Sinak C, Locher B, Ferrario CM, Sowers JR. Combination of direct renin inhibition with angiotensin type 1 receptor blockade improves aldosterone but does not improve kidney injury in the transgenic Ren2 rat. Regul Pept 2012;176:36-44.